Bristol Myers Squibb and SystImmune Report Positive Phase 3 Results for Iza-Bren in Breast Cancer

Bristol Myers Squibb and SystImmune reported that the Phase 3 PANKU-Breast01 trial met its primary endpoint in patients with HR+/HER2- advanced breast cancer. Izalontamab brengitecan (iza-bren) reduced the risk of disease progression or death by 59% versus chemotherapy, with median progression-free survival of 8.2 months compared with 4.0 months. The confirmed objective response rate was 40.5% with iza-bren versus 20.2% with chemotherapy. Results were presented at the ESMO 2026 Annual Congress and published in The Lancet; the article did not report financial results or a stock-price impact.